perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 1 Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with

#### 2 HIV - responses to SARS-CoV-2, variants of concern and circulating

#### 3 coronaviruses

- 4 Ane Ogbe<sup>\*1</sup>, Mathew Pace<sup>\*1</sup>, Mustapha Bittaye<sup>\*4</sup>, Timothy Tipoe<sup>1</sup>, Sandra Adele<sup>1</sup>,
- 5 Jasmini Alagaratnam<sup>6,7</sup>, Parvinder K Aley<sup>8</sup>, M. Azim Ansari<sup>1</sup>, Anna Bara<sup>9</sup>, Samantha
- 6 Broadhead<sup>13</sup>, Anthony Brown<sup>1</sup>, Helen Brown<sup>1</sup>, Federica Cappuccini<sup>4</sup>, Paola
- 7 Cinardo<sup>10</sup>, Wanwisa Dejnirattisai<sup>11</sup>, Katie J. Ewer<sup>4</sup>, Henry Fok<sup>10</sup>, Pedro M. Folegatti<sup>4</sup>,
- 8 Jamie Fowler<sup>4</sup>, Leila Godfrey<sup>4</sup>, Anna L. Goodman<sup>10</sup>, Bethany Jackson<sup>10</sup>, Daniel
- 9 Jenkin<sup>4</sup>, Mathew Jones<sup>1</sup>, Stephanie Longet<sup>11,12</sup>, Rebecca Makinson<sup>4</sup>, Natalie G.
- 10 Marchevsky<sup>8</sup>, Moncy Mathew<sup>10</sup>, Andrea Mazzella<sup>10</sup>, Yama F. Mujadidi<sup>8</sup>, Lucia
- <sup>11</sup> Parolini<sup>1</sup>, Claire Petersen <sup>6,7</sup>, Emma Plested<sup>8</sup>, Katrina M. Pollock<sup>9</sup>, Thurkka
- 12 Rajeswaran<sup>10</sup> Maheshi N. Ramasamy<sup>8</sup>, Sarah Rhead<sup>8</sup>, Hannah Robinson<sup>8</sup>, Nicola
- 13 Robinson<sup>1,3</sup>, Helen Sanders<sup>4</sup>, Sonia Serrano<sup>13</sup>, Helen Stockmann<sup>7</sup>, Tom Tipton<sup>11,12</sup>,
- 14 Anele Waters<sup>10</sup>, Panagiota Zacharopoulou<sup>1</sup>, Eleanor Barnes<sup>1,2,3,4</sup>, Susanna
- 15 Dunachie<sup>1,2,14,15</sup>, Philip Goulder<sup>1,2,5</sup>, Paul Klenerman<sup>1,2,3</sup>, Gavin R. Screaton<sup>11</sup>, Alan
- 16 Winston<sup>6,7</sup>, Adrian V. S. Hill<sup>4</sup>, Sarah C. Gilbert<sup>4</sup>, Miles Carroll<sup>11,12</sup>, Andrew J
- 17 Pollard<sup>\*3,8</sup>, Sarah Fidler<sup>\*6,7</sup>, Julie Fox<sup>10,13\*</sup>, Teresa Lambe<sup>\*4</sup>, John Frater<sup>\*1,2,3</sup>
- 18
- <sup>1</sup>Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical Medicine,
   University of Oxford, Oxford, UK
- 21 <sup>2</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- <sup>22</sup> <sup>3</sup>NIHR Oxford Biomedical Research Centre, Oxford, UK
- <sup>4</sup>The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford,
   UK
- <sup>5</sup>Department of Paediatrics, University of Oxford, Oxford, UK
- <sup>6</sup>Department of Infectious Disease, Faculty of Medicine, Imperial College London,
- 27 London, UK
- <sup>7</sup>Department of HIV Medicine, St Mary's Hospital, Imperial College Healthcare NHS
   Trust, London, UK
- <sup>8</sup>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
- <sup>9</sup>NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research
   Centre, London, UK
- <sup>10</sup>Department of Infection, Harrison Wing and NIHR Clinical Research Facility, Guys
   and St Thomas' NHS Trust, London, UK
- <sup>35</sup> <sup>11</sup>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University
- 36 of Oxford, Oxford, UK
- <sup>12</sup>Public Health England, Porton Down, UK.
- <sup>13</sup>NIHR Guy's and St Thomas' Biomedical Research Centre
- <sup>14</sup>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
- 40 University of Oxford, Oxford, UK
- <sup>15</sup>Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok,
- 42 Thailand
- 43
- 44 \*Contributed equally
- 45 46
- 47 **ODFREISportclemete to:** research that has not been certified by peer review and should not be used to guide clinical practice.

- 48 John Frater, Peter Medawar Building for Pathogen Research, Nuffield Dept of
- 49 Clinical Medicine, University of Oxford, Oxford, UK, OX1 3SY;
- john.frater@ndm.ox.ac.uk 50
- 51 Ane Ogbe, Peter Medawar Building for Pathogen Research, Nuffield Dept of Clinical
- Medicine, University of Oxford, Oxford, UK, OX1 3SY; ane.ogbe@ndm.ox.ac.uk 52

#### 54 Author Contributions

JFr, Ao, SF, JFo, TL. AJP, SCG, AVSH, AA, KJE were involved in conceptualisation, 55 data curation, funding acquisition, supervision, methodology, writing and reviewing the 56 manuscript. AO, MP, SA, EA, MA, AA, AB, HB, MJ, LP, NR, TT, PZ were involved with 57 sample methodology and preparation, assay performance, data curation (CTV 58 assays), data analysis and writing and reviewing the manuscript. EB, SD, PG, PK were 59 60 involved in supervision, data curation, investigation, methodology and writing and reviewing the manuscript. SL, ToT, MC oversaw MSD and ACE-inhibition assays; JA, 61 62 AB, CP, KMP, HS, AW, SF managed study recruitment at Imperial; PC, AM, TR, BJ, MM, SB, HK, ALG, SS, AW, JFo managed study recruitment at Guy's; WD, GRS were 63 involved in data curation (neutralisation), formal analysis, methodology and writing and 64 reviewing the manuscript. AB, JA, CP, KP, HS, AW, SF were involved in data curation, 65 methodology, project administration, supervision, investigation and writing and 66 reviewing the manuscript. PA was involved in project administration. MB, FC, PF, 67 JFow, DJ, RM, TL were involved in data curation, formal analysis, investigation, 68 methodology and writing and reviewing the manuscript. SB, HF, ALG, SS, AW, JFox 69 were involved in data curation, methodology, project administration, supervision, 70 investigation and writing and reviewing the manuscript. NGM, YM, EP, MR, SR, HR, 71 MV, AJP were involved in data curation, formal analysis, investigation, methodology 72 73 and writing and reviewing the manuscript. All authors critically reviewed and approved the final version. 74

#### 76 Abstract

Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following 77 vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial 78 (NCT04400838), 54 HIV positive male participants on antiretroviral therapy 79 (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1 80 81 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to 82 vaccination were determined by serology (IgG ELISA and MesoScale Discovery (MSD)), neutralisation, ACE-2 inhibition, gamma interferon ELISpot, activation-83 84 induced marker (AIM) assay and T cell proliferation. We show that 6 months after vaccination the majority of measurable immune responses were greater than pre-85 vaccination baseline, but with evidence of a decline in both humoral and cell mediated 86 immunity. There was, however, no significant difference compared to a cohort of HIV-87 uninfected individuals vaccinated with the same regimen. Responses to the variants 88 89 of concern were detectable, although were lower than wild type. Pre-existing crossreactive T cell responses to SARS-CoV-2 spike were associated with greater post-90 vaccine immunity and correlated with prior exposure to beta coronaviruses. These 91 data support the on-going policy to vaccinate PWH against SARS-CoV-2, and 92 underpin the need for long-term monitoring of responses after vaccination. 93

#### 95 Introduction

The global COVID-19 pandemic has led to over 200 million cases and 4.2 million 96 deaths (1). Vaccines which have been licensed against SARS-CoV-2 include the 97 AstraZeneca ChAdOx1 nCov-19 (AZD1222) adenoviral vectored vaccine, of which 98 over 1 billion doses have been made available worldwide. People living with HIV 99 (PWH) represent a high-risk group for adverse clinical outcomes from viral infections 100 101 such as influenza and COVID-19, with some evidence for higher hospitalisation and mortality rates (2-6). This can in part be attributed to a state of immune cell depletion 102 103 and chronic immunopathology including immune activation and exhaustion which is only partially restored by antiretroviral therapy (ART)(7, 8). Studies on influenza and 104 tetanus toxin vaccination in PWH have shown that antibody levels post-vaccination 105 106 were dependent on CD4 T cell count and activated T follicular helper (Tfh) cell frequencies, which can vary widely in PWH (9, 10), resulting in broader concerns over 107 reduced responses to vaccines (11) and specific vaccination guidelines for PWH (12). 108 Some studies also report that vaccination of PWH may induce immune activation and 109 reactivate the HIV reservoir (13, 14). 110

111

ChAdOx1 nCov-19 containing SARS-CoV-2 full length spike has been shown to 112 induce potent humoral and cellular immune response in vaccine recipients (15-18). 113 114 We recently reported the safety and immunogenicity of the ChAdOx1 nCoV-19 115 vaccine in PWH up to 2 months post initial vaccination (16) and the durability of T and B cell responses following natural infection with SARS-CoV-2 (19). There are, 116 117 however, few studies evaluating the durability of immunity following vaccination against COVID-19 (20, 21). A recent open label phase I trial showed durable SARS-118 CoV-2 T and B cell immune response up to 6 months following vaccination in adults 119

without HIV using a low dose of mRNA vaccine mRNA-1273 (21), with similar results
in another study using standard mRNA-1273 dosing (22). There have been no studies
to date reporting the durability of immune responses in PWH.

123

Since the rollout of COVID-19 vaccines, divergent mutations in the viral sequence in 124 the original SARS-CoV-2 strain have given rise to the alpha (B.1.1.7), beta (B.1.351), 125 126 gamma (P.1), and more recently delta (B.1.617.2) variants of concern (VOCs). Infections with VOCs have become dominant in several countries (23). Studies of 127 128 symptomatic disease in fully vaccinated individuals report variable effectiveness (ChAdOx1 nCoV-19 – alpha (74%), delta (67%) and BNT162b2 – alpha (93.7%), delta 129 (88%)), but with evidence for sustained protection from severe disease (24-26). 130 131 Nonetheless, breakthrough infections have been recorded and a significant proportion of the world's population remains unvaccinated (27). Understanding the ability of 132 immune responses generated in PWH to recognise VOCs is key to informing 133 vaccination strategies, especially in vulnerable populations. 134

135

Pre-existing cross-reactive T and B cell responses in individuals naïve to SARS-CoV-2 infection and vaccination to the circulating common cold coronaviruses (CCC) HKU1, OC43, 299E and NL63 have been identified (28-34), however the impact of this cross-reactivity is unclear. While some reports point to a beneficial role in mitigating disease severity and the induction of neutralising antibodies in both vaccination and natural infection (33, 35, 36), others report no biological function (37, 38) or a potential pathological role (39).

143

In this open-label, non-randomised sub-study of male participants with HIV on ART (CD4+ T cell count >350 cells/ul) receiving ChAdOx1 nCoV-19, we investigate the immunological landscape six months after vaccination. We evaluate the durability of the cellular and humoral immune response to SARS-CoV-2 and VOCs and assess the potential role of cross-reactive CCC immune responses in the modulation of postvaccine responses, presenting evidence for an interaction with the beta coronaviruses, HKU1 and OC43.

- 151
- 152 **Results**

#### 153 Participants

PWH (N=54; all male) were recruited as part of the ChAdOx1 nCoV-19 COV002 154 clinical trial (NCT04400838) in November 2020. Participants had undetectable VL 155 (<50 HIV RNA copies/ml) and a median CD4 count of 694 cells/µl (IQR 573.5 – 859.5) 156 at the time of recruitment. Most participants were of white ethnicity (81.5%). Other 157 reported ethnicities were Asian (3.7%), mixed (7.4%) and other (7.4%). 158 Demographically-matched HIV seronegative controls were provided from the 159 ChAdOx1 nCoV-19 COV002 clinical trial. All participants received ChAdOx1 nCoV-19 160 4-6 weeks apart and were followed for 6 months (Figure 1a, Table 1). 161

162

#### 163 Persistent immune activation in PWH before and after vaccination

T cell immune activation and exhaustion were assayed at day 0 baseline, day 42 and day 182 after first ChAdOx1 nCoV-19 vaccination (Figure 1b-g). There were significantly higher frequencies of CD38+ HLA-DR+ expressing CD4+ and CD8+ cells in PWH compared to HIV negative controls, consistent across all timepoints (Figure 168 1b and e, gating strategy in supplementary figure 1a). There was a transient

increase in the frequency of CD38+ HLA-DR+ CD4 and CD8+ T cells 14 days after 169 vaccination in PWH which returned to pre-vaccination levels by 6 months 170 (Supplementary figure 1c, f). Expression of the immune checkpoint inhibitor PD-1 171 on CD4+ and CD8+ T cells was not significantly different between PWH and HIV 172 negative controls with no statistically significant changes after vaccination (Figure 1c 173 and f). The frequency of CD4+ and CD8+ PD-1 expressing cells fluctuated early after 174 175 vaccination in PWH but was restored to pre-vaccination levels at 6 months (supplementary figure d, g, j and m). The frequency of functionally exhausted Tbet 176 177 (lo) Eomesodermin (Eomes) (hi) CD4+ and CD8+ T cells was higher in PWH compared to HIV-negative individuals both before and after vaccination. (Figure 1d 178 179 and g, supplementary figure 1e, h, k and n).

180

#### 181 Humoral immunity against ChAdOx1 nCoV-19 in PWH persists for 6 months.

We previously reported detectable antibody levels up to 56 days following ChAdOx1 182 nCoV-19 vaccination in PWH (16). To determine the further persistence of antibody 183 responses, total IgG for spike (S), receptor binding domain (RBD) and nucleocapsid 184 (N), as well as neutralising antibody levels were measured at days 0 and day 182. 185 Two independent ELISA technologies were used for binding IgG assays: a 186 standardised in-house total IgG against spike and Meso Scale Discovery (MSD) 187 188 binding assays measuring S, RBD and N antibody levels. Levels of anti-spike IgG 189 measured using the two assays were positively correlated (Supplementary figure 2a and b, r=0.7, p<0.0001 and r = 0.9, p<0.0001 at Days 0 and 182, respectively; 190 191 Spearman). At day 182 post-vaccination, antibodies to S and RBD but not N were significantly higher than at baseline (S: day 0 = 3/43 [6.9%], day 182 = 35/42 [83.3%]; 192

193 RBD: day 0 = 0/43 [0%] and day 182 = 27/42 [64.2%]) (**Figure 2a** – **c**), consistent with 194 observed responses being driven by vaccination rather than infection.

195

Importantly, there was no difference in anti-spike antibody titres in HIV+ and HIVmatched participants measured at 182 days after first vaccination, although with some waning of responses in both groups after Day 56 (Figure 2d; Supplementary Figure 2d,e). Pre-vaccine baseline antibody titres correlated positively with early postvaccination timepoints at day 14, and 28 but not 42, 56 and 182 (Supplementary figure 2f, Supplementary table 1).

202

203 We next assessed the ability of antibodies from plasma collected 6 months after 204 vaccination to compete with SARS-CoV-2 for binding to ACE-2 using an ACE-2 inhibition assay and to neutralise SARS-CoV-2 using a live virus focus reduction 205 206 neutralisation assay (FRNT). FRNT was performed in a randomly selected subset of the cohort for whom we have previously reported neutralisation antibody levels up to 207 208 day 56 (16). At day 182 post-ChAdOx1 nCoV-19 prime, antibodies capable of blocking 209 the SARS-CoV-2 ACE-2 interaction were present at significantly higher levels than at 210 pre-vaccination baseline (Figure 2e) and correlated strongly with anti-RBD antibodies 211 (Supplementary figure 2c). However, at the same time point antibody neutralisation 212 measured by FRNT live virus assay revealed titres below the assay detection limit in nearly all participants (13/14; 92%) (Figure 2f). 213

214

Durable SARS-CoV-2 specific T cell responses are induced following ChAdOx1
 nCoV-19 vaccination

Durability of vaccine-induced SARS-CoV-2-specific T cell immunity at 6 months was
assessed by IFNγ ELISpot and T cell proliferation assays. SARS-CoV-2 spike-specific

ELISpot responses were maintained for 6 months in PWH following vaccination and were equivalent to the HIV negative control group (Figure 3a and b; Supplementary figure 4a).

222

For further resolution of the durability of T cell immunity, we used a T cell proliferation 223 assay which also allows distinction of different CD4 and CD8 T cell lineage responses. 224 225 The spike peptide pool was separated into S1 and S2. Gating strategy is shown in **Supplementary Figure 3a**. The frequency of SARS-CoV-2 spike-specific proliferative 226 227 CD4+ and CD8+ T cell responses in PWH following vaccination were maintained at levels significantly higher than at baseline for 6 months (Figure 3c - f). Longitudinal 228 responses to FECT controls remained unchanged while PHA responses were back to 229 230 baseline by day 182 (Supplementary figure 3b and c). There was no difference in 231 the magnitude of the vaccine-specific T cell proliferative responses between the HIV+ and the HIV- cohorts (Supplementary Figure 4f - I). Although T cell responses in 232 PWH measured by IFNy ELISpot peaked at day 14 and were then maintained to day 233 182, proliferative responses peaked later at day 42 and then contracted, such that day 234 182 responses were significantly lower than those measured at day 56 (Figure 3c-f). 235 These kinetics are similar to those observed with the anti-S antibody response 236 (Supplementary figure 2d and e). 237

238

Vaccine-reactive T cells are not differentially biased to a specific CD4+ subset.
Using CCR6 and CXCR3 expression to quantify Th1, Th2 and Th17 cells, we
interrogated the phenotype of circulating T cells following vaccination (gating strategy
in Supplementary Figure 1a). At 6 months post ChAdOx1 nCoV-19 vaccination, we
found redistributions in the phenotype of the CD4+ T cells in HIV+ volunteers with

increases in Th1 (CXCR3+ CCR6-) and Th2 (CXCR3- CCR6-) (Figure 4a and b) but
not Th17 (CXCR3- CCR6+) or Tfh (CXCR5+ CD4+) (Figure 4c and d). None of these
populations correlated with anti-spike antibody levels 6 months after infection.
Although the hierarchy in cellular composition of the CD4+ T cell subsets was similar
in the HIV+ and HIV- cohorts, we found circulating frequencies of Th2 subsets to be
reduced while Th1 and Tfh subsets were significantly increased 6 months after
vaccination in PWH (Figure 4e, Supplementary Figure 5a – for HIV- control data).

251

252 The activation induced marker (AIM) assay was used to determine the phenotype of vaccine-specific CD4+ T cells 6 months after ChAdOx1 nCoV-19 vaccination (gating 253 strategy in **Supplementary figure 5b**). Vaccine responses were compared with 254 255 concurrent HIV Gag and CMV responses (Figure 4f and g). Although AIM+ cells for all antigens tested showed a Th17 bias (Supplementary Figure 5c), similar to HIV-256 Gag or CMVpp65-specific T cells there was no preferential skewing of the SARS-CoV-257 2-specific T responses to any CD4 T helper subset 6 months after vaccination (Figure 258 259 4h - k).

260

Responses to variants of concerns (VOCs) are preserved 6 months after
 vaccination

Humoral and cellular immune responses to the major VOCs were measured 6 months after vaccination. Inhibition of ACE-2 binding for alpha, beta and gamma variants was increased compared to pre-vaccination baseline (**Figure 5a**), however there was statistically significant reduction in ACE-2 inhibition for all three VOCs compared to the original SARS-CoV-2 strain, which was more apparent in the beta and gamma variants (**Figure 5b**). T cell proliferative responses to VOCs were comparable to the

SARS-CoV-2 original strain, except for SARS-CoV-2 CD4 responses to S2 which were moderately reduced across all VOCs tested (Figure 5c – f). HIV+ and HIVparticipants had similar magnitudes of T cell responses to S1 and S2 spike proteins of all VOCs tested, with the exception of the CD8+ SARS-CoV-2 T cell proliferative response targeting the S2 protein of the delta variant which showed a modest reduction in HIV+ participants compared to HIV- controls (Figure 5g – j).

275

276 Modulation of ChAdOx1 nCoV-19 post vaccination responses by pre-existing
 277 cross-reactive immunity

SARS-CoV-2 reactive T and B cells exist in unvaccinated COVID-19 naïve individuals
(Figure 3a – e, Supplementary figure 2d and e). To determine whether these prevaccine responses might reflect cross-reactivity to endemic circulating coronaviruses
of the alpha (NL63 and 299E) or beta (HKU1, OC43) genera, we also measured
responses to these viruses at baseline.

283

Based on the T cell proliferation assay, participants were divided according to those 284 with pre-vaccine baseline SARS-CoV-2 immune responses ('baseline responders', 285 (BR)) and those without pre-existing immunity ('baseline non-responders', (B-NR)). 286 Regardless of any pre-existing immunity, all donors mounted an immune response 287 following vaccination, however BR consistently showed higher magnitude CD4+ 288 (Figure 6a and b) and CD8+ T cell (Supplementary Figure 6a and b) responses to 289 SARS-CoV-2 S1 and S2 at most post-vaccination timepoints. Baseline SARS-CoV-2 290 291 CD4+ S2 (and to a lesser extent S1) T cell proliferation was positively correlated with subsequent post-vaccine proliferative responses targeting the same regions 292

293 (Supplementary Figure 7b and c, supplementary table 2a - d), which is of potential

interest as S2 is associated with regions of homology to other coronaviruses.

T cell and IgG responses to the endemic CCCs (HKU1 (clade 1 and 2), OC43, 299E and NL63) in HIV-infected participants remained mostly unchanged by vaccination with ChAdOx1 nCov-19 indicating that vaccination did not boost these responses (**Figure 7c, Supplementary Figure 8 and 9**) however, IgG responses to SARS-CoV-1 and MERS-CoV in PWH were higher at 6 months (**Figure 7a,b**).

300

301 Focusing on baseline pre-existing responses – and dividing the cohort of PWH into the SARS-CoV-2 BR and B-NR groups as before - participants with baseline 302 proliferative T cell responses to SARS-CoV-2 spike, also had T cell responses 303 targeting the S2 spike regions of CCCs, especially for the beta coronaviruses HKU1 304 and OC43 and alpha coronavirus 299E (Figure 6c and d, Supplementary Figure 6c 305 and d, Supplementary table 3). This was supported by humoral responses taken at 306 the same pre-vaccination timepoint, which showed strong correlations between 307 SARS-Cov-2 spike IgG levels and those of SARS-CoV-1, MERS-CoV-1 and HKU1 308 (Figure 7d-f; Supplementary Figure 9, supplementary table 4). Phylogenetic 309 analysis of spike sequences shows OC43 and HKU1 are the mostly closely related 310 CCCs to SARS-CoV-2 (Figure 7g). These data suggest that prior exposure to beta 311 312 coronaviruses and responses to the S2 homologous region may potentially be associated with larger and more persistent T cell responses following SARS-CoV-2 313 vaccination. 314

#### 315 Discussion

316 Long-lasting immune responses against SARS-CoV-2 will be necessary to confer protection from severe COVID-19. Although clinical management and effective 317 antiretroviral therapy (ART) have improved long-term outcomes for PWH – especially 318 in resource-rich countries – HIV-induced immunopathology evidenced by immune 319 320 activation and exhaustion does not recover to the levels found in HIV uninfected 321 subjects (40), raising concerns whether effective immune responses will persist after vaccination. We show here for the first time in PWH that vaccine-induced immunity to 322 323 SARS-CoV-2 persists for at least 6 months by most assays, but with evidence that responses are starting to wane. There were no significant differences in responses by 324 PWH and HIV- controls, extending the data from short-term responses reported 325 previously (16, 41). 326

327

We confirm the persistent immune activation - and, to a lesser degree, functional 328 exhaustion - in T cells in PWH on ART, but show that this does not impact the robust 329 humoral and cellular immune responses to ChAdOx nCoV-19 that persist for 6 months. 330 Reports on reactivation of the HIV reservoir and increased immune activation after 331 vaccination in PWH are conflicting (13, 14, 42), and although we found a transient 332 increase in the frequencies of T cells co-expressing CD38 and HLA-DR, this was 333 334 restored to baseline by six months. Further studies will be needed to determine any 335 impact on the HIV reservoir.

336

Vaccine design and regimen can skew the quality of the T cell response by the
preferential induction of one CD4+ T helper subset over another (43-48). ChAdOx-1
nCoV-19 responses show a qualitative skew towards the Th1 phenotype, with

increased IFNγ, IL-2 and TNF-producing T cells shortly after vaccination (18). Other
studies in convalescent cohorts have linked a CCR6+ Th-17 cTfh phenotype with
reduced disease severity (49). Similar to others (44, 50), we found antigen-specific
CD4+T cells following vaccination were mostly a CCR6+ CXCR3- Th-17 phenotype.
We did not find SARS-CoV-2 spike-specific CD4+ T cells biased towards any
chemokine-expressing sub-population 6 months after vaccination, possibly reflecting
the longer duration between vaccination and analysis than in other studies.

347

348 Understanding durability of both humoral and cellular immunity to SARS-CoV-2 – both likely key components of an effective response (49, 51, 52) - is key to understanding 349 long-term protection. When we assessed the longevity of the humoral and cellular 350 351 immunity in PWH 6 months after ChAdOx1 nCoV-19 vaccination, we found that vaccine-mediated antibodies to spike or RBD remained elevated above baseline and 352 no different to HIV- controls. Similarly, T cell responses to spike were maintained at 353 magnitudes above baseline and demonstrated similar kinetics to HIV- participants. 354 Antibody function measured by ACE-2 binding inhibition was sustained at levels above 355 pre-vaccination, however live neutralisation assays did not detect antibodies in the 356 majority of the participants assayed at 6 months. Both assays identified the same 357 participants as low (n = 13) and high (n = 1) responders, and the ACE-2 binding 358 359 inhibition and SARS-CoV-2 RBD titres showed a strong positive correlation. We 360 speculate that although differences in positive responses between the two functional assays could be as a result of function (neutralisation) versus antigenicity (ACE-2 361 binding inhibition), it could also in part, be due to assay sensitivity and differing 362 dynamic ranges between assays. 363

364

SARS-CoV-2 convalescent plasma has been shown to have effective FC-mediated 365 antibody functions such as antibody dependent cellular phagocytosis (ADCP), 366 367 antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) (53-55), which are more durable than neutralisation (54). Non-368 neutralising functions were not evaluated in this study, and therefore we cannot 369 exclude that these are preserved in this cohort of PWH. Total spike IgG antibody and 370 371 T cell proliferative responses in PWH were significantly lower at 6 months after vaccination compared to day 56. These results suggest detectable but waning T and 372 373 B cell responses at 6 months. Similar findings were reported for the mRNA-1273 COVID-19 vaccine, and found to be age-dependent, pointing to immune aging as a 374 contributing factor (20, 21). This comprehensive analysis of humoral and cellular 375 376 immunity is consistent with studies of COVID-19 in healthy adults and PWH showing durable immune responses up to 7 months post infection (19, 52, 56, 57). Further 377 378 follow up at 12 months and beyond will be important to determine the longer-term persistence of responses, especially when considering the value of booster doses. 379

380

The emergence of VOCs poses a potential roadblock to ending the pandemic. We 381 found humoral immunity to VOCs at 6 months to be at titres lower than those targeting 382 the original wild type (WT) SARS-CoV-2 strain, albeit still significantly higher than pre-383 vaccination levels. The magnitude of the T cell responses to VOCs were similar to 384 385 those targeting the WT SARS-CoV-2 strain for most VOCs tested apart from the CD4+ S2 responses. For most of the VOCs, T cell responses in PWH did not differ from HIV-386 controls. Similar observations regarding humoral immunity have been made with the 387 mRNA vaccine BNT162b2 although as most of these studies were done within 2 388 months of vaccination, information on durability of the response is lacking (58-60). 389

One study assessing T cell responses between 21 – 28 days after full BNT162b2 vaccination found no differences between WT and VOC CD4 responses (58). This study utilised a pool of spike peptide pools not parsed into its S1 and S2 regions, and only a limited panel of VOCs were analysed. Importantly, emerging data from real world effectiveness studies suggest that vaccination protects against death and severe disease, even following infection with VOCs (24, 26)

396

Cross-reactivity from previous CCC infection may impact the measured SARS-CoV-2 397 398 immune response after vaccination and natural infection (32, 33, 61). We identified measurable pre-vaccine antibody titres for SARS-CoV-2 S, RBD and N proteins in 399 PWH. Pre-vaccination SARS-CoV-2 S antibody levels strongly correlated with those 400 of contemporaneous beta coronaviruses SARS-CoV-1, MERS-CoV and HKU1 (of 401 402 which only the latter is likely to have been experienced by these UK study participants), 403 supporting the hypothesis that these titres result from previous infection with a similar coronavirus and some cross-reactivity across coronaviruses. Supporting the antibody 404 data, the presence of cross-reactive T cells pre-vaccination (based on proliferative 405 406 potential following antigen challenge) was associated with higher magnitude postvaccination T cell responses. 407

408

There is much debate over the significance of cross-reactive responses. Studies have reported reduced disease severity in patients with CCC humoral responses and regions of high homology to CCC capable of trans-priming SARS-CoV-2 T and B cell responses (32, 33, 36). Pre-existing immunity was also shown to boost post vaccine responses in low dose mRNA-1273 vaccine (21) although an explanatory mechanism was not reported. Further investigations in large studies would be needed to fully

elucidate the impact of baseline pre-existing immunity in post-vaccination response,
but we find clear evidence of higher magnitude immune responses in those with crossreactivity. Although our data suggest that responses to CCC may help augment
subsequent vaccine responses against SARS-CoV-2, we have no evidence that on
their own they are potent enough to impact susceptibility to COVID-19.

420

421 In summary, we present a comprehensive immunological assessment of ChAdOx1 nCoV-19 in PWH 6 months after vaccination. We show that despite persistent immune 422 423 activation in PWH, PWH on ART and HIV-uninfected participants make equivalent T and B cell responses following vaccination. However, both responses showed signs 424 of decline after 6 months. It is unknown what level of immunity is required to prevent 425 hospitalisation and mortality, but real-world data suggest vaccination is successful in 426 preventing severe disease and death even in the presence of transmissible and 427 428 virulent VOC (24, 26). A booster dose may become necessary in the future to maintain long-term immunological memory to SARS-CoV-2 and the VOCs, especially for 429 susceptible cohorts and we must continue to carefully monitor this going forward. 430 Finally, we demonstrate that pre-existing SARS-CoV-2 cross-reactive immune 431 responses to the beta coronaviruses HKU1 and to a lesser extent OC43 are 432 associated with higher magnitude T cell responses following vaccination in PWH. 433 434 Together these data continue to reinforce the policy of ensuring all PWH are offered vaccination against SARS-CoV-2. 435

#### 436 Methods

#### 437 Study design and cohort

438 The cohort studied in this analysis has been described previously (16). Briefly, the 439 study comprised people living with HIV in an open-label non-randomised group within 440 the larger multicentre phase 2/3 COV002 trial. The participants in this single-arm group comprised individuals with HIV who were stable on ART under routine follow-up at two 441 London UK National Health Service (NHS) clinics and received ChAdOx1 nCoV-19 442 vaccination according to the schedule of attendance. Recruitment was done in HIV 443 clinics at two centres in the UK (Imperial College NHS Trust and Guy's and St Thomas' 444 445 NHS Foundation Trust). Inclusion criteria were age 18–55 years, a diagnosis of HIV infection, virological suppression on ART at enrolment (plasma HIV viral load <50 446 447 copies per mL), and a CD4 count of more than 350 cells/µL. The inclusion criteria for 448 the COV002 trial have been published in full elsewhere (15). Written informed consent was obtained from all participants, and the trial was done in accordance with the 449 principles of the Declaration of Helsinki and Good Clinical Practice. Study approval in 450 the UK was done by the Medicines and Healthcare products Regulatory Agency 451 (reference 21584/0424/001-0001) and the South Central Berkshire Research Ethics 452 453 Committee (reference 20/SC/0145). Vaccine use was authorised by Genetically 454 Modified Organisms Safety Committees at each participating site.

The ChAdOx1 nCoV-19 vaccine was produced as previously described (17). Participants received two standard intramuscular doses 4–6 weeks apart. For some assays and where sample availability allowed, comparison was made with age- and sex-matched participants who were HIV negative, aged 18–55 years, enrolled into the main COV002 phase 2/3 randomised clinical trial, and randomly assigned (5:1) to receive either ChAdOx1 nCoV-19 or MenACWY by intramuscular vaccination. The

dose of vaccine administered was the same across both groups. Only participants
receiving the ChAdOx1 nCoV-19 vaccine were used for comparison. Full details of the
COV002 HIV-negative cohort have been published previously (15).

464 A screening visit where a full medical history, examination of all participants and blood tests to exclude biochemical or haematological abnormalities (full blood count; kidney 465 466 and liver function tests) was done prior to enrolment. Participants with a history of 467 laboratory-confirmed SARS-CoV-2 infection by anti-N protein IgG immunoassay 468 (Abbott Architect, Abbott Park, IL, USA) at screening were excluded. For this study, visits on day 0 (vaccine prime) and 182 were the main study timepoints used for 469 immunological analysis however for some assays other study visits - 14, 28 (vaccine 470 471 boost), 42, and 56 - are presented where available. As some participants did not attend 472 for their day 182 visit (n=6), there is a maximum of n=48 at this timepoint.

473

#### 474 Mesoscale Discovery (MSD) binding assays

475 lqG responses to SARS-CoV-2, SARS-CoV-1, MERS-CoV and 476 seasonal coronaviruses were measured using a multiplexed MSD immunoassay. The V-PLEX COVID-19 Coronavirus Panel 3 (IgG) Kit (cat. no. K15399U) from Meso Scale 477 478 Diagnostics, Rockville, MD USA. A MULTI-SPOT<sup>®</sup> 96-well, 10 spot plate was coated 479 with three SARS CoV-2 antigens (S, RBD, N), SARS-CoV-1 and MERS-CoV spike 480 trimers, as well as spike proteins from seasonal human coronaviruses, HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-NL63, and bovine serum albumin. Antigens 481 were spotted at 200–400 µg/mL (MSD<sup>®</sup> Coronavirus Plate 3). Multiplex MSD assays 482 were performed as per the instructions of the manufacturer. To measure IgG 483 484 antibodies, 96-well plates were blocked with MSD Blocker A for 30 minutes. Following washing with washing buffer, samples diluted 1:1,000-10,000 in diluent buffer, or MSD 485

standard or undiluted internal MSD controls, were added to the wells. After 2-hour 486 incubation and a washing step, detection antibody (MSD SULFO-TAG<sup>™</sup> Anti-Human 487 IgG Antibody, 1/200) was added. Following washing, MSD GOLD™ Read Buffer B 488 was added and plates were read using a MESO® SECTOR S 600 Reader. The 489 standard curve was established by fitting the signals from the standard using a 4-490 491 parameter logistic model. Concentrations of samples were determined from the 492 electrochemiluminescence signals by back-fitting to the standard curve and multiplied by the dilution factor. Concentrations are expressed in Arbitrary Units/ml (AU/ml). Cut-493 494 offs were determined for each SARS-CoV-2 antigen (S, RBD and N) based on the concentrations measured in 103 pre-pandemic sera + 3 Standard Deviations. Cut-off 495 for S: 1160 AU/ml; cut-off for RBD: 1169 AU/ml; cut-off for N: 3874 AU/ml. 496

497

#### 498 SARS CoV-2 spike IgG ELISA

499 Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS CoV-2 spike protein as described 500 previously<sup>21</sup>. In brief, ELISA plates were coated with 2 µg/mL of full-length trimerised 501 SARS-CoV-2 spike glycoprotein and stored at 4°C overnight for at least 16 hours. After 502 coating, plates were washed 6 times with PBS/0.05%Tween and blocked with casein 503 for 1h at room temperature (RT). Thawed samples were treated with 10% Triton X-504 505 100 for 1h at RT and subsequently diluted in casein and plated in triplicate for 506 incubation for 2h at RT alongside two internal positive controls (controls 1 and 2) to measure plate to plate variation. Control 1 was a dilution of convalescent plasma 507 508 sample and control 2 was a research reagent for anti-SARS-CoV-2 Ab (code 20/130 supplied by National Institute for Biological Standards and Control (NIBSC)). The 509 standard pool was used in a two-fold serial dilution to produce ten standard points that 510

were assigned arbitrary ELISA units (EUs). Goat anti-human IgG (y-chain specific) 511 conjugated to alkaline phosphatase was used as secondary antibody and plates were 512 513 developed by adding 4-nitrophenyl phosphate in diethanolamine substrate buffer. An ELx808 microplate reader (BioTek Instruments) was used to provide optical density 514 measurement of the plates at 405mm. Standardised EUs were determined from a 515 single dilution of each sample against the standard curve which was plotted using the 516 517 4-Parameter logistic model (Gen5 v3.09, BioTek). Each assay plate consisted of 518 samples and controls plated in triplicate, with ten standard points in duplicate and four 519 blank wells. The assay LLOQ (representing the lowest IgG titres that can be reliably and precisely quantified within a coefficient of variation of 25%) was determined 520 mathematically. This was based on the 4-PL function of the standard curve data from 521 250 independent experiments and represents the EU value corresponding to the 522 upper 95% confidence interval of the minimum asymptote of the 4-PL curve fit used 523 524 for modelling the assay standard curves. The value of 13 EU was calculated as the assay LLOQ and this corresponds to an OD value of 0.2 for which the assay was 525 demonstrated to show linearity. 526

527

#### 528 Focus reduction neutralization assay (FRNT)

Antibody neutralization was measured in a randomly selected subset of participants using a Focus Reduction Neutralization Test (FRNT), as described previously (62) where the reduction in the number of the infected foci is compared to a 'no antibody' negative control well. Briefly, serially diluted Ab or plasma was mixed with SARS-CoV-2 strain Victoria and incubated for 1 hour at 37°C. The mixtures were then transferred to 96-well, cell culture-treated, flat-bottom microplate containing confluent Vero cell monolayers in duplicate and incubated for further 2 hours, followed by the addition of

1.5% semi-solid carboxymethyl cellulose (CMC) overlay medium to each well to limit 536 virus diffusion. A focus forming assay was then performed by staining Vero cells with 537 human anti-NP mAb (mAb206) followed by peroxidase-conjugated goat anti-human 538 IgG (A0170; Sigma). Finally, the foci (infected cells) approximately 100 per well in the 539 absence of antibodies, were visualized by adding TrueBlue Peroxidase Substrate. 540 Virus-infected cell foci were counted on the classic AID ELISpot reader using AID 541 542 ELISpot software. The percentage of focus reduction was calculated and IC50 (reported as FRNT50) was determined using the probit program from the SPSS 543 544 package.

545

#### 546 MSD ACE-2 inhibition assay

A multiplexed MSD immunoassay (MSD, Rockville, MD) was used to measure the 547 ability of human sera to inhibit ACE2 binding to SRAS-CoV-2 spike (B, B.1, 548 B.1.1.7, B.1.351 or P.1). A MULTI-SPOT® 96-well, 10 Spot Plate (Plate 7) was 549 coated with eight SARS-CoV-2 spike and RBD antigens (B. B.1. B.1.1.7, B.1.351) 550 or P.1). Multiplex MSD Assays were performed as per manufacturer's instructions. 551 To measure ACE2 inhibition, 96-well plates were blocked with MSD blocker for 30 552 minutes. Plates were then washed in MSD washing buffer, and samples were 553 diluted 1:10 and 1:100 in diluent buffer. Importantly, an ACE2 calibration curve 554 which consists of a monoclonal antibody with equivalent activity against spike 555 556 variants was used to interpolate results as arbitrary units. Furthermore, internal controls and the WHO international standard were added to each plate. After 1-557 558 hour incubation recombinant human ACE2-SULFO-TAG<sup>™</sup> was added to all wells. After a further 1-hour plates were washed and MSD GOLD<sup>™</sup> Read Buffer B was 559

added, plates were then immediately read using a MESO® SECTOR S 600Reader.

562

### 563 Isolation of peripheral blood mononuclear cells (PBMC) from whole blood

PBMCs were isolated by density gradient centrifugation using Lymphoprep (Stem Cell 564 Technologies, Cambridge, UK). Buffy coats containing PBMCs were collected and 565 566 washed twice with pre-warmed R10 medium: Roswell Park Memorial Institute (also known as RPMI) 1640 medium (Sigma Aldrich, St Louis, MO, USA) supplemented 567 568 with 10% heat-inactivated fetal calf serum (FCS; Sigma), 1 mM penicillin-streptomycin solution (Sigma), and 2 mM L-glutamine solution (Sigma). After the second 569 centrifugation, cells were resuspended in R10 and counted using the Guava ViaCount 570 571 assay (Guava Technologies Hayward, CA, USA) on the Muse Cell Analyzer (Luminex Cooperation). T-cell enzyme-linked immunospot assay (ELISpot) assays were done 572 on freshly isolated PBMCs, and CellTrace Violet (CTV; ThermoFisher Scientific, CA, 573 USA) T cell proliferation assay was done on cryopreserved samples. 574

575

#### 576 Ex vivo IFNg ELISpot to enumerate antigen-specific T cells.

ELISpot assays were performed as described previously (17) using a validated 577 protocol with freshly isolated peripheral blood mononuclear cells (PBMCs) to 578 579 determine responses to the SARS-CoV-2 spike vaccine antigen at days 0 (before 580 vaccination), 14, 28 (boost), 42 and 56. Assays were performed using Multiscreen IP ELISpot plates (Merck Millipore, Watford, UK) coated with 10 µg/mL human anti-IFNy 581 582 antibody and developed using SA-ALP antibody conjugate kits (Mabtech, Stockholm, Sweden) and BCIP NBT-plus chromogenic substrate (Moss Inc., Pasadena, MA, 583 USA). PBMC were separated from whole blood with lithium heparin by density 584

centrifugation within four hours of venepuncture. Cells were incubated for 18-20 hours 585 in RPMI (Sigma) containing 1000 units/mL penicillin, 1 mg/mL streptomycin and 10% 586 heat-inactivated, sterile-filtered foetal calf serum, previously screened for low reactivity 587 (Labtech International, East Sussex, UK) with a final concentration of 10µg/ml of each 588 peptide. A total of 253 synthetic peptides (15mers overlapping by 10 amino acids) 589 590 spanning the entire vaccine insert, including the tPA leader sequence were used to 591 stimulate PBMC (Prolmmune, Oxford UK). Peptides were pooled into 12 pools for the SARS-CoV-2 spike protein containing 18 to 24 peptides, plus a single pool of 5 592 593 peptides for the tPA leader. Peptides were tested in triplicate, with  $2.5 \times 10^5$  PBMC added to each well of the ELISpot plate in a final volume of 100µL. Results are 594 expressed as spot forming cells (SFC) per million PBMCs, calculated by subtracting 595 596 the mean negative control response from the mean of each peptide pool response and then summing the response for the 12 peptide pools spanning S1 and S2. 597 Staphylococcal enterotoxin B (0.02 µg/mL) and phytohaemagglutinin-L (10 µg/ mL) 598 were pooled and used as a positive control. Plates were counted using an AID 599 automated ELISpot counter (AID Diagnostika GmbH, algorithm C, Strassberg, 600 Germany) using identical settings for all plates, and counts were adjusted only to 601 remove artefacts. A lower limit of detection of 48 SFC/million PBMCs was determined 602 based on the minimum number of spots that could be detected. 603

604

#### 605 T cell proliferation assay

T cell proliferation assay was done using cryopreserved PBMCs. Briefly, PBMCs were thawed and washed twice with 1mL of PBS followed by labelling with CTV at a final concentration of  $2.5 \mu$ M for 10 min at room temperature. CTV, a DNA intercalating dye, enables the measurement of the decrease in dye concentration following each

610 cell division in proliferating cells in response to antigenic stimulation as described previously (34). The labelling reaction was guenched with 4mL of fetal bovine serum 611 612 (FBS) at 4°C and cells were resuspended in RPMI medium supplemented with 10% human blood group type AB serum (Sigma), 1 mM penicillin-streptomycin solution, 613 and 2 mM L-glutamine solution, and subsequently plated in a 96-well round bottom 614 plate at a plating density of  $0.25 \times 10^6$  cells per well in duplicate wells (total of 615 616  $0.5 \times 10^6$  cells per condition). Cells were stimulated with peptide pools (15nmers) overlapping by 11) spanning SARS-CoV-2 spike (S1 and S2), SARS-CoV-2 variants 617 618 of concern (beta, gamma and delta) and HCoVs (HKU-1 – 2 consensus clades, OC43, NL63 and 299E) at a final concentration of 1 µg/mL per peptide. For antigenic control, 619 class 1 and 2 optimal peptides for FEC-T (flu, EBV, CMV, and tetanus) were pooled 620 621 at a final concentration of 1 µg/mL per peptide. Media, containing 0.1% dimethyl sulfoxide (DMSO; Sigma) representing DMSO content in peptide pools, was used as 622 623 a negative control and 2 µg/mL phytohaemagglutinin L (Sigma) was used as positive control. Cells were then incubated at 37°C, with 5% carbon dioxide and 95% humidity 624 for 7 days, with a change of media on day 4. At the end of the incubation period, cells 625 were stained using anti-human CD3, CD4, CD8, and a live cell discriminator 626 (Live/Dead near Infra-red, Life Technologies; ThermoFisher Scientific, CA, USA) as in 627 supplementary table 5. All samples were acquired using a BD Fortessa X20 (BD 628 Bioscience, San Jose, CA, USA) or MACSQuant x10 (Miltenyi Biotec, Bergisch 629 630 Gladbach, Germany). Responses above 1% were considered true positive based mean of DMSO controls + 3x SD. Specificity of the assay has been previous reported 631 632 in (34). All datapoints presented represent a single participant and are presented as background subtracted data. 633

634

#### 635 AIM Assay

Cryopreserved PBMCs from 25 HIV infected subjects were used for activation induced 636 637 marker (AIM) assay. Briefly, PBMCs were thawed in R10 (RPMI + 10% FCS, 1% Pen/strep and 1% L-glutamine. Cells were washed, counted, and rested for 6 hours in 638 IMDM-10 (Iscove's Modified Dulbecco's Medium - Sigma, I3390 + 10% Human AB 639 serum, 1% Pen/strep and 1% L-glutamine) and 1ul/ml of benzonase nucleases 640 641 (70746-3, Merck). Following rest, cells were plated at 1-2 x10<sup>6</sup> cells/well in a 96 well round bottom plate. Cells were then incubated for 24 hours at 37°C and 5% CO2. After 642 643 stimulation cells were stained with the anti-human antibodies contained in supplementary table 6. Stained cells were fixed in 4% PFA and acquired on a BD 644 LSR II flow cytometer. The data was analysed using FlowJo version 10 and Prism 645 version 9. Antigen-specific CD4+ and CD8+ T cells were gated using the gating 646 strategy described by Nielsen et al (44) and shown in supplementary figure 5 (for 647 CD4 T cells: CD25+ CD134(OX40)+ and CD25+ CD137+ and CD25+ CD69+; for 648 CD8+ T cells: CD25+ CD137+ and CD25+ CD69+). Chemokine receptors CCR6 and 649 CXCR3 were used as an unbiased way of analysing T cell skewness independent of 650 cytokine kinetics. 651

652

#### 653 Ex vivo activation and exhaustion assays

654 Cryopreserved PBMCS were thawed in 30mls of RPMI media supplemented with 10% 655 FBS, 1% Pen-strep and 1% L-glutamine (R10). Cells were counted and rested for an 656 hour at a cell density of 2 x 10<sup>6</sup> per ml of R10 in the presence of benzonase 657 endonucleases (70746-3, Merck). Following rest, 2-3 million cells were used for each 658 of the panels. Cells were washed in staining buffer (420201, Biolegend). This was 659 followed by blocking FC receptors (422302, Biolegend) for 10 minutes at room

temperature (RT) and live cell staining using L/D agua (L34966, Life Technologies). All 660 cells were then washed in preparation for antibody staining. For ex vivo 661 immune activation panel, antibodies for assessing immune activation (as listed 662 in supplementary table 7) was used as a cocktail and added to the cell pellet. Cells 663 were subsequently incubated at 37°C for 15 minutes which was followed by 664 a wash and fixation in 4% paraformaldehyde (PFA) for 10 minutes at RT. PFA was 665 666 washed off and cells resuspended in PBS for acquisition on flow cytometer. For immune exhaustion panel, antibodies for surface markers were prepared in a cocktail 667 668 which was added to cells and incubated for 15 minutes at 37°C (supplementary table 669 8). Cells were then prepared for intranuclear stain usina FOXP3 fixation/permeabilisation kit (Life technologies). Briefly, 100ul of fixation buffer was 670 671 added to cells and incubated at RT for 30 minutes. This was followed by cellular permeabilisation using the permeabilisation buffer contained in the aforementioned kit. 672 Antibody cocktails were prepared in permeabilisation buffer, added to cells and 673 allowed to incubate for 30 minutes at RT. Following staining, cells were washed and 674 resuspended in PBS for acquisition. All data was acquired on a BD LSR II flow 675 cytometer and fluorescent minus one (FMO) gates were used to set gates for markers 676 of interest. Gating strategies are as shown in supplementary figure 1a and b 677

678

#### 679 *Phylogenetic analysis*

We used protein BLAST to download all human coronavirus S protein sequences from NCBI database. We then randomly chose 3 sequences for each of the human coronavirus species. HKU1 was consisted of two clades and we chose three isolates for each clade (c1 and c2). We used MAFFT to align all chosen human corona viruses, SARS-CoV, MERS-CoV and SARS-CoV-2 S protein sequences. We then calculated

the pairwise distances between the sequences and built a neighbour joining tree usingMATLAB.

687

#### 688 Statistical analysis

This study was not powered to a specific endpoint and the sample size was based on 689 practical recruitment considerations in line with other subgroups of the COV002 study. 690 691 We analysed all outcomes in all participants who received both doses of the vaccination schedule and with available samples, unless otherwise specified. We log-692 693 transformed serological, FRNT50, and ELISpot data for analysis. FRNT50 titres less than 20 were given the value 10 for statistical analysis. We present medians and IQRs 694 for immunological endpoints. We used non-parametric analysis (Spearman's rho) for 695 696 correlations between two immunological endpoints. For comparison of two nonparametrically distributed unpaired variables, we used the Wilcoxon rank sum (Mann 697 Whitney U) test. For comparison of two non-parametrically distributed paired datasets, 698 we used the Wilcoxon matched pairs signed rank test. We used the  $\chi^2$  test for 699 comparison of ELISpot responses. Missing data were not imputed. We did all analyses 700 using R (version 3.6.1 or later), and Prism 9 (GraphPad Software). The COV002 study 701 is registered with ClinicalTrials.gov, NCT04400838, and is ongoing. 702

703

#### 704 Role of the funding source

The funders of the study had no role in the study design, data collection, data analysis,
data interpretation, or writing of the report. All authors had full access to all the data in
the study and had final responsibility for the decision to submit for publication.

708

#### 709 Acknowledgements

710 This Article reports independent research funded by UK Research and Innovation (MC PC 19055), 711 Engineering and Physical Sciences Research Council (EP/R013756/1), Coalition for Epidemic Preparedness Innovations, and NIHR. We 712 acknowledge support from Thames Valley and South Midland's NIHR Clinical 713 Research Network and the staff and resources of NIHR Southampton Clinical 714 715 Research Facility and the NIHR Oxford Health Biomedical Research Centre. PMF received funding from the Coordenacao de Aperfeicoamento de Pessoal de Nivel 716 717 Superior, Brazil (finance code 001). ALF was supported by the Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China (grant number 2018-718 I2M-2-002). MAA is supported by the Wellcome Trust and Royal Society 719 720 (220171/Z/20/Z). KJE is an NIHR Biomedical Research Centre senior research fellow. AJP and EB are NIHR senior investigators. M.C., S.L. and ToT. are funded by a U.S. 721 722 Food and Drug Administration Medical Countermeasures Initiative grant 75F40120C00085. The views expressed in this publication are those of the authors 723 and not necessarily those of the NIHR, FDA or the UK Department of Health and 724 Social Care. We thank the volunteers who participated in this study. 725

726

#### 727 Declaration of interests

Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19 (AZD1222). AstraZeneca reviewed the data from the study and the final manuscript before submission, but the authors retained editorial control. SCG is cofounder of Vaccitech (a collaborator in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1vectored vaccines (PCT/GB2012/000467) and a patent application covering this

SARS-CoV-2 vaccine. TL is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and was consultant to Vaccitech. PMF is a consultant to Vaccitech. AJP is Chair of the UK Department of Health and Social Care's JCVI, but does not participate in policy advice on coronavirus vaccines, and is a member of the WHO Strategic Advisory Group of Experts (SAGE). AVSH is a cofounder of and consultant to Vaccitech and is named as an inventor on a patent covering design and use of ChAdOx1-vectored vaccines (PCT/GB2012/000467).

#### Tables and table legend

#### Table 1: Demographic information for HIV infected and HIV uninfected receiving ChAdOx1 nCoV-19

		HIV infected	HIV uninfected	
Assay		All reported assays	ELISpot and ELISA	Activation/Exhaustion Panel, proliferation assay, and AIM assay
n		54	50	10
Sex	Male	54 (100%)	26 (52%)	10 (100%)
	Female	0 (0%)	24 (48%)	0 (0%)
Age in years		42.5 (37.2 - 49.8)	38.5 (29.2 - 45.0)	
Ethnicity	White	44 (81%)	40 (80%)	6 (60%)
	Black	0 (0%)	1 (2%)	1 (10%)
	Asian	2 (4%)	8 (16%)	2 (20%)
	Mixed	4 (7%)	0 (0%)	0 (0%)
	Other	4 (7%)	1 (2%)	1 (10%)
Antiretroviral therapy	Y	54 (100%)	NA	NA
	N		NA	NA
Plasma HIV VL		<50	NA	NA
CD4 count > 350 cells/ul		694.0 (573.5 - 859.5)	NA	NA

#### 748 Figures and Figure Legends

#### 749



Figure 1: PLWH show higher baseline immune activation and exhaustion

750

751

752 Figure 1: PWH show higher baseline immune activation and exhaustion.

A) Schematic showing vaccination schedule for ChAdOx1 nCoV-19 in PWH. Frequency of (B) CD38+ HLA-DR+, (C) PD1+ (D)

- Tbet(lo) Eomes(hi) cells within CD4+ and (E) CD38+ HLA-DR+, (F) PD1+ (G) Tbet(lo) Eomes(hi) cells within CD8+ T cells.
- Comparison of two groups by two-tailed Mann-Whitney U test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = <0.001 and \*\*\*\* = <0.0001.



Figure 2: Antibody levels against SARS-CoV-2 6 months after ChAdOx1 nCoV-19 vaccination

# 756

#### 757

#### 758 Figure 2: Antibody levels against SARS-CoV-2 6 months after ChAdOx1 nCoV-19 vaccination.

IgG levels for SARS-CoV-2 (A) Spike (B) RBD and (C) N protein measured at day 0 (baseline) and day 182 (6 months postvaccination) using the MSD ELISA assays. (D) Comparison between antibody kinetics in HIV+ and HIV- across all available timepoints. (E) ACE-2 inhibition assay at baseline and 6 months post-vaccination and (F) Live-virus focus reduction neutralisation assay (FRNT) on n =15 HIV+ donors on day 0, 28, 56 and 182. Comparison of two timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Comparison of two groups was done by two-tailed Mann-Whitney U test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001 and \*\*\*\* = <0.000. Dotted lines in A – C indicate cut off points determined for each SARS-CoV-2 antigen (S, RBD and N) based on pre-pandemic sera + 3X SD.

#### Figure 3: T cell responses following ChAdOx1 nCoV-19 vaccination are durable in PWH.



767 768

## 769 Figure 3: T cell responses following ChAdOx1 nCoV-19 vaccination are durable in PWH.

(A) T cell response measured using peptides pools against SARS-CoV-2 S1 and S2 antigens by IFN $\gamma$  ELISpot across all timepoints. (B) comparative analysis of IFN $\gamma$  T cell responses in HIV+ and HIV-volunteers. Proliferative T cell responses to (C) SARS-CoV-2 S1 and (D) SARS-CoV-2 S2 in CD4+ T cells across all available timepoints. Proliferative T cell responses to (E) SARS-CoV-2 S1 and (F) SARS-CoV-2 S2 in CD8+ T cells across all available timepoints. Comparison of two timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Comparison of two groups was done by two-tailed Mann-Whitney U test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001 and \*\*\*\* = <0.000. Dotted lines in C - F indicate threshold for true positive based mean of DMSO controls + 3x SD.



Figure 4: SARS-CoV-2 specific T cells are not preferentially biased for any CD4+ T cell subsets

#### 777 778

## 779 Figure 4: SARS-CoV-2 specific T cells are not preferentially biased for any CD4+ T cell subsets.

Ex vivo frequencies of (A) CXCR3+ CCR6- (Th1), (B) CXCR3- CCR6- (Th2), (C) CXCR3- CCR6+ (Th17), and (D) CXCR5+ within 780 CD4+ T cells in HIV+ volunteers measured at day 0, 42 and 182 using ex vivo T cell phenotyping. (E) comparative analysis of 781 782 frequencies of ex vivo CD4+ T cell frequencies in HIV+ and HIV- volunteers at day 182 (6 months post vaccination). Measurement 783 of frequencies of antigen specific T cells including SARS-CoV-2 S1 and S2, HIV gag and CMVpp65 using activation induced marker (AIM) assay in (F) CD4+ and (G) CD8+ T cells. For CD4 T cells, antigen specific cells were: CD25+ CD134(OX40)+ and CD25+ 784 785 CD137+ and CD25+ CD69+; for CD8+ T cells, antigen specific cells were: CD25+ CD137+ and CD25+ CD69+ Frequencies of (H) CXCR3+ CCR6-(Th1), (I) CXCR3- CCR6- (Th2), (J) CXCR3- CCR6+ (Th17), and (K) CXCR5+ CD4+ T cells within antigen specific 786 (AIM+) T cells in HIV+ volunteers. Comparison of two timepoints within the same group was done by Wilcoxon matched pair sign 787 788 ranked test. Comparison of two groups was done by two-tailed Mann-Whitney U test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001 and \*\*\*\* = <0.000. 789



#### Figure 5: Responses to VOCs are preserved at 6 months post ChAdOx1 nCoV-19 vaccination in PWH

#### 790

#### 791 Figure 5: Responses to VOCs are preserved at 6 months post ChAdOx1 nCoV-19 vaccination in PWH.

792 (A) ACE-2 binding inhibition assay for alpha, beta and gamma VOCs measured at day 0 (baseline) and at day 182 (6 months postvaccination) in HIV+ volunteers. (B) Comparison between ACE-2 binding inhibition of SARS-CoV-2 WT strain and alpha, beta and 793 gamma VOCs in HIV+ volunteers. Comparison between proliferative T cell responses to SARS-CoV-2 WT strain and beta, gamma 794 795 and delta VOCs in (C) CD4+ S1, (D) CD4+ S2, (E) CD8+ S1 and (F) CD8+ S2 in HIV+ volunteers. Comparative analysis of (G) CD4+ S1, (H) CD4+ S2, (I) CD8+ S1, and (J) CD8+ S2 T cells responses to VOCs in HIV+ (solid circles) and HIV- (open circles). Comparison 796 of two timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Comparison of two groups was done 797 by two-tailed Mann-Whitney U test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = <0.001 and \*\*\*\* = <0.000. Dotted lines in C- J indicate 798 threshold for true positive based mean of DMSO controls + 3x SD. 799



Figure 6: Pre-existing cross-reactive CD4+ T cell responses in PWH measured at baseline are associated with high magnitude T cell

801 802

800

Figure 6: Pre-existing cross-reactive CD4+ T cell responses in PWH measured at baseline are associated with high magnitude T cell responses post ChAdOx1 nCoV-19 vaccination.

Baseline CD4+ SARS-CoV-2 responses were split into baseline responders (BR, proliferation >1%, black circles and black lines) and 805 baseline non-responders (B-NR, Proliferation <1%, yellow circles and yellow lines) and CD4 T cell responses post vaccination were 806 analysed at all available timepoints for (A) SARS-CoV-2 S1 and (B) SARS-CoV-2 S2. T cells responses targeting (C) S1 and (D) S2 807 proteins in endemic CCCs are measured at baseline in BR and B-NR. Comparison of two timepoints within the same group was done 808 by Wilcoxon matched pair sign ranked test. Comparison of two groups was done by two-tailed multiple Mann-Whitney U test. CCC 809 responses among participants were compared using fisher's exact test and listed in supplementary table 3. P values as indicated or 810 \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001 and \*\*\*\* = <0.000. Dotted lines in indicate threshold for true positive based mean of DMSO controls 811 + 3x SD 812





#### 813

#### 814 Figure 7: Cross reactive humoral immune responses among betaCoVs.

Antibody titres against (A) SARS-CoV, (B) MERS-CoV, and (C) HKU-1 spike proteins measured at day 0 (baseline) and day 182 (6
 months post-vaccination) in HIV+ participants. Correlation between baseline antibody titres for SARS-CoV-2 and (D) SARS-CoV-1,
 (E) MERS-CoV, and (F) HKU-1 spike protein at baseline. (G) Phylogenetic tree showing relationship between coronaviruses.
 Correlation was performed via Spearman's rank correlation coefficient and comparison of two timepoints within the same group was
 done by Wilcoxon matched pair sign ranked test. Where indicated ns = not significant, \* = <0.05, \*\* = <0.01, \*\*\* = <0.001 and \*\*\*\* =</li>
 <0.0001. Dotted lines in A – B indicate cut off points determined for each SARS-CoV-2 antigen based on pre-pandemic sera + 3X</li>
 SD.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

#### 822 Supplementary figure legends

823

#### 824 Supplementary figure 1: Flow cytometry gating strategy and kinetics of cells 825 expressing activation and exhaustion marker.

Gating strategy for (A) activation panel and (B) exhaustion panel. All gates were set 826 827 based on fluorescent minus one (FMO). Frequency of cells expressing (C) CD38+ HLA DR+, (D) PD-1+, (E) Eomes(hi) Tbet(lo) within CD4+ T cells on HIV+ participants 828 and frequency of cells expressing (F) CD38+ HLA DR+, (G) PD-1+, (H) Eomes(hi) 829 Tbet(lo) within CD8+ T cells on HIV+ participants. Frequency of cells expressing (I) 830 CD38+ HLA DR+, (J) PD-1+, (K) Eomes(hi) Tbet(lo) within CD4+ T cells on HIV-831 832 participants and frequency of cells expressing (L) CD38+ HLA DR+, (M) PD-1+, (N) Eomes(hi) Tbet(lo) within CD8+ T cells on HIV- participants. Comparison of two 833 834 timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001 and \*\*\*\* = <0.001 835

836 837

# Supplementary figure 2: Humoral immune responses against SARS-CoV-2 in PWH.

(A) Correlations between antibody levels measured using MSD assay and in-house 840 total IgG ELISA at (A) day 0, (B) day 182 and (C) correlations between day 182 SARS-841 CoV-2 RBD levels and ACE-2 binding inhibition assay. (D) Antibody levels in HIV+ 842 participants measured across all timepoints presented as dot plots and, (E) before-843 after plots to show individual responses. (F) Correlation plot showing correlation matrix 844 845 between SARS-CoV-2 humoral immune response across all proteins, assays and timepoints. Correlation was performed via Spearman's rank correlation coefficient and 846 847 correlation matrix was created using corrplot package on R studio. Size and Colour of 848 the heatmap corresponds to the correlation coefficient. Comparison of two timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Where 849 indicated \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001 and \*\*\*\* = <0.0001. 850

851 852

# Supplementary figure 3: Gating strategy and T cell response to control antigens (FECT) and mitogen (PHA).

(A) Gating strategy for proliferation assay. All gates were set based on DMSO controls. 855 Background was subtracted and responses were assigned positive if they were >1% 856 857 after background subtraction. (B) PHA responses in CD4+ and CD8+ T cells at longitudinal timepoints. (C) FECT responses in CD4+ and CD8+ T cells at longitudinal 858 timepoints. Comparison of two timepoints within the same group was done by 859 860 Wilcoxon matched pair sign ranked test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* =< 0.001 and \*\*\*\* = <0.000. Dotted lines in indicate threshold for true positive based 861 mean of DMSO controls + 3x SD. 862

- 863
- 864
- 865

#### 866 Supplementary figure 4: Longitudinal T cell responses to SARS-CoV-2 in HIV+ 867 and HIV- subjects following ChAdOx1 nCoV-19 vaccination.

(A) IFNγ ELISpot responses in HIV- volunteers at day 0, 42 and 182. T cell proliferative
 response to (B) SARS-CoV-2 S1, (C) SARS-CoV-2 S2 in CD4+ T cells in HIV volunteers and T cell proliferative response to (D) SARS-CoV-2 S1, (E) SARS-CoV-2
 S2 in CD8+ T cells in HIV- volunteers. Comparison of T cell proliferative responses to

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

872 **(F)** SARS-CoV-2 S1, **(G)** SARS-CoV-2 S2 in CD4+ T cells **(H)** SARS-CoV-2 S1, **(I)** 873 SARS-CoV-2 S2 in CD8+ T cells in HIV+ and HIV negative volunteers at day 0, 42 874 and 182. Comparison of two timepoints within the same group was done by Wilcoxon 875 matched pair sign ranked test. Comparison of two groups was done by two-tailed 876 multiple Mann-Whitney U test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001 877 and \*\*\*\* = <0.000. Dotted lines in indicate threshold for true positive based mean of 878 DMSO controls + 3x SD.

879 880

## 881 Supplementary figure 5: Phenotype of total and SARS-CoV-2 S-specific 882 circulating CD4+ T cells

(A) Ex vivo frequencies of (A) CXCR3+ CCR6+ (Th1), CXCR3- CCR6- (Th2), CXCR3-883 884 CCR6+ (Th17), and CXCR5+ within CD4+ T cells in HIV- volunteers measured at 885 various timepoints. (B) gating strategy for AIM assay. All cells expressing CD25+ CD134 (OX40) and CD25+ CD137+ and CD25+ CD69+ were Boolean gated as 886 antigen specific cells. Gating was set based on DMSO control and all responses were 887 888 background subtracted. CXCR3 and CCR6 guadrant gate for antigen specific population was set based on expression in bulk CD4 T cell population. (C) Frequency 889 of CD4 T cell subsets in SEB, SARS-CoV-2 S1, SARS-CoV-2 S2, HIV GAG and 890 891 CMVpp65. Comparison of two timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Comparison of two groups was done by two-892 tailed multiple Mann-Whitney U test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = < 893 894 0.001 and \*\*\*\* = <0.000.

895 896

# Supplementary figure 6: Pre-existing cross-reactive immunity in PWH measured at baseline are associated with high magnitude CD8+ T cell responses post ChAdOx1 nCoV-19 vaccination

Baseline CD8+ SARS-CoV-2 responses were split into baseline responders (BR, 900 901 proliferation >1%, black circles and black lines) and baseline non-responders (B-NR, 902 Proliferation <1%, yellow circles and yellow lines) and CD8 T cell responses post 903 vaccination were analysed at all available timepoints for (A) SARS-CoV-2 S1 and (B) SARS-CoV-2 S2. T cells responses targeting (C) S1 and (D) S2 proteins in endemic 904 905 CCCs are measured at baseline in BR and B-NR. Comparison of two timepoints within 906 the same group was done by Wilcoxon matched pair sign ranked test. Comparison of 907 two groups was done by two-tailed multiple Mann-Whitney U test. CCC responses among participants were compared using fisher's exact test and listed in 908 909 supplementary table 3. P values as indicated or \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001910 and \*\*\*\* = <0.000. Dotted lines in indicate threshold for true positive based mean of DMSO controls + 3x SD. 911

912

913

# Supplementary figure 7: Relationship between baseline and post vaccination. timepoints for CD4+ and CD8+ proliferative T cells.

916 Correlation plots showing correlation matrix for (A) CD4+ SARS-CoV-2 S1, (B) CD4+ 917 SARS-CoV-2 S2, (C) CD8+ SARS-CoV-2 S1, (D) CD8+ SARS-CoV-2 S2. Correlation 918 was performed via Spearman's rank correlation coefficient and correlation matrix was 919 created using corrplot package on R studio. Size and Colour of the heatmap 920 corresponds to the correlation coefficient. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = 921 < 0.001 and \*\*\*\* = <0.0001.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

#### Supplementary figure 8: Responses to CCC in PWH 922

T cell proliferative responses to CCCs HKU-1 clade 1 and 2, OC43, 299E, NL63 S1 923 and S2 in CD4+ and CD8+ T cells measured on day 0, 14, 28, 42, 56 and 182. 924 Comparison of two timepoints within the same group was done by Wilcoxon matched 925 pair sign ranked test. P values as indicated or \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001 and 926 \*\*\*\* = <0.000. Dotted lines in indicate threshold for true positive based mean of DMSO 927 controls + 3x SD. 928

929 930

#### Supplementary figure 9: Relationship between antibody responses for SARS-931 932 CoV-2 and CCCs spike in PWH

(A) Correlation plot showing correlation matrix between different circulating HCoVs. 933 934 (B) Antibody titres at day 0 and day 182 for OC43 Spike, 299E spike and NL63 spike 935 proteins in HIV+ participants. Correlation was performed via Spearman's rank 936 correlation coefficient and correlation matrix was created using corrplot package on R studio. Size and Colour of the heatmap corresponds to the correlation coefficient. 937 938 Comparison of two timepoints within the same group was done by Wilcoxon matched pair sign ranked test. Where indicated \* = <0.05, \*\* = <0.01, \*\*\* = < 0.001 and \*\*\*\* = 939 < 0.0001. 940

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

#### 941 References

WHO. WHO Coronavirus (COVID-19) Dashboard. In: World Health Organization; 942 1. 943 2021.

944 2. Mellor MM, Bast AC, Jones NR, Roberts NW, Ordóñez-Mena JM, Reith AJM, Butler 945 CC, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS 946 (London, England) 2021;35:F1-F10.

947 Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in 3. 948 HIV-infected adults: a review of the literature. Clinical infectious diseases : an official 949 publication of the Infectious Diseases Society of America 2011;52:219-227.

- 950 Abadom TR, Smith AD, Tempia S, Madhi SA, Cohen C, Cohen AL. Risk factors 4. 951 associated with hospitalisation for influenza-associated severe acute respiratory illness in 952 South Africa: A case-population study. Vaccine 2016;34:5649-5655.
- 953 5. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, Gonzalez CJ, et al. 954 COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New 955 York State. JAMA Netw Open 2021;4:e2037069.
- 956 Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, Villa G, et al. 6. 957 Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO 958 Clinical Characterization Protocol (UK): a prospective observational study. Clin Infect Dis 959 2020.
- 960 7. Martin GE, Sen DR, Pace M, Robinson N, Meyerowitz J, Adland E, Thornhill JP, et al. 961 Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral 962 Therapy. Frontiers in Immunology 2021;12:1458.
- 963 BHIVA. BHIVA guidelines on the use of vaccines in HIV-positive adults 2015. In. 8. 964 www.bhiva.org/vaccination-guidelines; 2021.
- 965 9. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, 966 tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the 967 number of CD4+ lymphocytes. AIDS (London, England) 1994;8:469-476.
- 968 10. Cole ME, Saeed Z, Shaw AT, Guo Y, Höschler K, Winston A, Cooke GS, et al. 969 Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell 970 Subsets in Men Living with HIV. Scientific Reports 2019;9:15650.
- 971 Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of 11. 972 influenza vaccination in individuals infected with HIV. Vaccine 2002;20:B29-B32.
- 973 Bridges CB, Fukuda K, Cox NJ, Singleton JA. Prevention and control of influenza. 12. 974 Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 975 Recomm Rep 2001;50:1-44.
- 976 13. Christensen-Quick A, Chaillon A, Yek C, Zanini F, Jordan P, Ignacio C, Caballero G, et 977 al. Influenza Vaccination Can Broadly Activate the HIV Reservoir During Antiretroviral
- 978 Therapy. Journal of acquired immune deficiency syndromes (1999) 2018;79:e104-e107.
- 979 14. Yek C, Gianella S, Plana M, Castro P, Scheffler K, García F, Massanella M, et al. 980 Standard vaccines increase HIV-1 transcription during antiretroviral therapy. AIDS (London, 981 England) 2016;30:2289-2298.
- 982 15. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR,
- 983 Voysey M, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a
- prime-boost regimen in young and old adults (COV002): a single-blind, randomised, 984
- 985 controlled, phase 2/3 trial. The Lancet 2020;396:1979-1993.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

986 16. Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, et al. Safety and 987 immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV 988 infection: a single-arm substudy of a phase 2/3 clinical trial. The Lancet HIV 2021. 989 Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, 17. 990 et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a 991 preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet 992 2020;396:467-478. 993 18. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, Flaxman 994 A, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 995 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine 2021;27:270-278. 996 Adriana T, Donal TS, Ane O, Daniel O, Connor\*, Matthew P, Emily A, et al. Divergent 19. 997 trajectories of antiviral memory after SARS-Cov-2 infection. Research Square 2021. 998 20. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell 999 JD, et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. New England 1000 Journal of Medicine 2020;384:80-82. 1001 21. Mateus J, Dan JM, Zhang Z, Moderbacher CR, Lammers M, Goodwin B, Sette A, et al. 1002 Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies 1003 enhanced by pre-existing crossreactive T cell memory. medRxiv 1004 2021:2021.2006.2030.21259787. 1005 Pegu A, O'Connell S, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, et al. Durability 22. 1006 of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science 1007 2021:eabj4176. 1008 EpiFlu G. Tracking of Variants. In: GISAID EpiFlu; 2021. 23. 1009 Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, et 24. 1010 al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England 1011 Journal of Medicine 2021. 1012 25. England PH. SARS-CoV-2 variants of concern and variants under investigation in 1013 England Technical briefing 15. In: PUBLIC HEALTH ENGLAND UK; 2021. 1014 Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, Fell DB, et al. 26. 1015 Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv 1016 2021:2021.2006.2028.21259420. 1017 27. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, et al. 1018 Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New England Journal of Medicine 2021. 1019 1020 28. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, Burger ZC, et al. Selective 1021 and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 2020;370:89. 1022 29. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, 1023 et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 1024 Disease and Unexposed Individuals. Cell 2020;181:1489-1501.e1415. 1025 Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, Hippenstiel S, et al. SARS-30. 1026 CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 2020;587:270-1027 274. 1028 31. Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C, et al. Pre-1029 existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection. 1030 medRxiv 2021:2021.2006.2026.21259239.

1031 32. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, et al. 1032 SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected 1033 controls. Nature 2020;584:457-462. 1034 33. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, et al. 1035 Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 1036 2020;370:1339. 1037 34. Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, Adair K, et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive 1038 1039 antiviral responses. Nature Communications 2021;12:2055. 1040 Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, Kern F, et al. Cross-35. 1041 reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and 1042 vaccination. medRxiv 2021:2021.2004.2001.21252379. 1043 36. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, Robinson ML, et al. Viral 1044 epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. 1045 Science 2020;370:eabd4250. 1046 37. Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatziioannou T, Bieniasz P. 1047 Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with 1048 recent seasonal coronavirus infection. Clin Infect Dis 2020. 1049 38. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, Gouma S, 1050 et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but 1051 not associated with protection. Cell 2021;184:1858-1864.e1810. 1052 39. McNaughton AL, Paton RS, Edmans M, Youngs J, Wellens J, Phalora P, Fyfe A, et al. 1053 Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes 1054 shared with endemic coronaviruses. medRxiv 2021:2021.2005.2004.21256571. 1055 40. Hileman CO, Funderburg NT. Inflammation, Immune Activation, and Antiretroviral 1056 Therapy in HIV. Current HIV/AIDS Reports 2017;14:93-100. 1057 41. Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD, et al. Safety 1058 and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in 1059 people living with and without HIV in South Africa: an interim analysis of a randomised, 1060 double-blind, placebo-controlled, phase 1B/2A trial. The Lancet HIV 2021;8:e568-e580. 1061 Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of 42. 1062 infection frequency, morbidity, mortality, and vaccine responses. The Lancet Infectious 1063 Diseases 2009;9:493-504. Golding B, Scott DE. Vaccine strategies: targeting helper T cell responses. 1064 43. Nielsen CM, Ogbe A, Pedroza-Pacheco I, Doeleman SE, Chen Y, Silk SE, Barrett JR, et 1065 44. 1066 al. Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T 1067 follicular helper cell responses than heterologous viral vectors. Cell Reports Medicine 1068 2021;2:100207. 1069 45. Taylor JM, Ziman ME, Canfield DR, Vajdy M, Solnick JV. Effects of a Th1- versus a Th2-1070 biased immune response in protection against Helicobacter pylori challenge in mice. 1071 Microbial pathogenesis 2008;44:20-27. 1072 46. Bowyer G, Grobbelaar A, Rampling T, Venkatraman N, Morelle D, Ballou RW, Hill 1073 AVS, et al. CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS, S/AS01B 1074 and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. Frontiers in Immunology 2018;9. 1075

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Bentebibel S-E, Khurana S, Schmitt N, Kurup P, Mueller C, Obermoser G, Palucka AK, 1076 47. 1077 et al. ICOS+PD-1+CXCR3+ T follicular helper cells contribute to the generation of high-avidity 1078 antibodies following influenza vaccination. Scientific Reports 2016;6:26494. 1079 Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, Takehara 48. 1080 KK, et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell 1081 2021;184:169-183.e117. 1082 49. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, 1083 Belanger S, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and 1084 Associations with Age and Disease Severity. Cell 2020;183:996-1012.e1019. 1085 Juno JA, Tan H-X, Lee WS, Reynaldi A, Kelly HG, Wragg K, Esterbauer R, et al. 50. 1086 Humoral and circulating follicular helper T cell responses in recovered patients with COVID-1087 19. Nature Medicine 2020;26:1428-1434. 51. 1088 Zhou R, To KK-W, Wong Y-C, Liu L, Zhou B, Li X, Huang H, et al. Acute SARS-CoV-2 1089 Infection Impairs Dendritic Cell and T Cell Responses. Immunity 2020;53:864-877.e865. 1090 52. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, et al. Immunological 1091 memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 1092 2021;371:eabf4063. 1093 Tso FY, Lidenge SJ, Poppe LK, Peña PB, Privatt SR, Bennett SJ, Ngowi JR, et al. 53. 1094 Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-1095 19 plasma. PLOS ONE 2021;16:e0247640. 1096 Lee WS, Selva KJ, Davis SK, Wines BD, Reynaldi A, Esterbauer R, Kelly HG, et al. Decay 54. 1097 of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Reports 1098 Medicine 2021;2:100296. 1099 Chen X, Rostad CA, Anderson LJ, Sun H-y, Lapp SA, Stephens K, Hussaini L, et al. The 55. 1100 development and kinetics of functional antibody-dependent cell-mediated cytotoxicity 1101 (ADCC) to SARS-CoV-2 spike protein. Virology 2021;559:1-9. 1102 56. Alrubayyi A, Gea-Mallorquí E, Touizer E, Hameiri-Bowen D, Kopycinski J, Charlton B, 1103 Fisher-Pearson N, et al. Characterization of humoral and SARS-CoV-2 specific T cell 1104 responses in people living with HIV. bioRxiv 2021:2021.2002.2015.431215. 1105 Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, et 57. 1106 al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 1107 2020;370:1227. 1108 58. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, Schmitz KS, et al. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses 1109 in COVID-19 convalescent donors and vaccine recipients. Science Immunology 1110 1111 2021;6:eabj1750. 1112 59. Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, Cai H, et al. Neutralizing 1113 Activity of BNT162b2-Elicited Serum. New England Journal of Medicine 2021;384:1466-1468. 1114 1115 60. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, et al. Antibody resistance of 1116 SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021;593:130-135. 1117 Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, Robinson ML, et al. Viral 61. 1118 epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. 1119 Science 2020;370:eabd4250. 1120 Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, Zhao Y, et al. Reduced 62. 1121 neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 1122 2021;184:2201-2211.e2207.